Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.
Objective: We aim to determine in a cell model neuroprotective effects of targeting lipoxygenases (LOXs), central players in Ferroptosis, a novel regulated iron-dependent cell death…Neuritic pathology in Parkinson’s Disease results from loss of anti-oxidant response activity
Objective: To determine the link between α-syn accumulation and neuritic pathology in Parkinson’s Disease (PD). Background: Neurological dysfunction in PD is highly associated with pathological…Disease-in-a-dish: drug discovery using patient-derived stem cells in Hereditary Spastic Paraplegia
Objective: Identify a drug treatment for Hereditary Spastic Paraplegia (HSP) using patient-derived stem cell models Background: HSP is a neurological disorder characterised by axonal degeneration…Role of microRNA-153 and -223 in Parkinson disease
Objective: To assess the therapeutic and diagnostic potential of microRNA (miR)-153 and miR-223 in mice and humans with parkinsonism. Background: Dysregulated miRNAs play a major…Gender-specific effects of uric acid on the development of freezing of gait in Parkinson’s disease
Objective: To investigate whether serum uric acid level is gender-specifically associated with the development of freezing of gait (FOG) in patients with de novo Parkinson’s…Beneficial and protective effects of Terminalia chebula in a murine model of Parkinson’s disease
Objective: Present study was designed to investigate whether Terminalia chebula (TC) extract would prevent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced neurotoxicity in male Wistar rats. Background: Parkinson's disease (PD)…High-throughput screening using a Drosophila model of Parkinson’s disease
Objective: To identify potential therapeutic compounds for Parkinson’s disease (PD) treatment by combining a phenotype-based high-throughput screening assay in PD model flies with a validation…Nrf2 pathway in patients with Parkinson’s disease
Objective: To demonstrate the activation of Nuclear factor erythroid-2-related factor 2 (Nrf2) pathway in PD patients. Background: Experimental data indicated the critical involvement of Nrf2…Serum non-mercaptalbumin as a potential biomarker in Parkinson’s disease and related disorders
Objective: To investigate the oxidized albumin ratio, which is the redox ratio of human non-mercaptalbumin (HNA) to serum albumin (HSA) (%HNA), as a biomarker in…Resistance to Parkinson’s disease among LRRK2 mutation carriers is associated with higher plasma levels of urate but not its purine precursors
Objective: To determine whether plasma purine concentrations differ between people with Parkinson's disease (PD) and matched controls among carriers of pathogenic mutations in Leucine-Rich Repeat…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.